Does Hormonal Therapy Have a Therapeutic Role in Metastatic Primary Small Cell Neuroendocrine Breast Carcinoma? Case Report and Literature Review

Alkaied, Homam; Harris, Kassem; Brenner, Arnold; Awasum, Michael; Varma, Seema

doi:10.1016/j.clbc.2012.01.008

Cited by 9 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression of NE markers is not consistent in the very rare SCNC of the breast subtype, however 8,12. More than 80% to 90% of SCNC express progesterone receptor (PR) and/or estrogen receptor (ER),13 with only 50% to 67% of SCNC subtypes expressing ER and/or PR; one third of SCNCs can be negative for both receptors 14. In SCNC, morphological behavior alone can be relied upon to confirm the diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Primary small-cell neuroendocrine carcinoma of the male breast: a rare case report with review of the literature

Jiang¹,

Wang²,

Li³

et al. 2014

OTT

View full text Add to dashboard Cite

In this case study and review, we present a case of a primary small-cell neuroendocrine carcinoma (SCNC) of the male breast. Primary SCNC of the breast is a rare tumor with less than 30 cases reported in the literature. Most cases are found in women. Another exceptional point is that human epidermal growth factor receptor-2 (Her-2) immunoreactivity was positive in our recent case, which differed to previous reports detailing SCNC in women. We have no evidence to demonstrate the differences between treatment and prognoses for males and females, because we do not have sufficient cases to undertake an evidence-based investigation. We provide this rare case history; review the literature on SCNC of the breast; and discuss detailed information regarding epidemiology, histogenesis, clinical and histologic diagnosis criteria, surgical and adjuvant treatment, and prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Primary small-cell neuroendocrine carcinoma of the male breast: a rare case report with review of the literature

Jiang¹,

Wang²,

Li³

et al. 2014

OTT

View full text Add to dashboard Cite

show abstract

“…In hormone receptor-positive breast cancer patients, hormonal therapy has been shown to improve breast cancer mortality [23,24]. Hormonal therapy may be a treatment option for small cell carcinoma of the breast who express hormone receptors as it has been shown to have some benefit in case reports [25,26]. The majority of small cell carcinoma of the breast patients in this study expressed TOP2A.…”

Section: Discussionmentioning

confidence: 77%

Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung

McCullar

Pandey

Yaghmour

et al. 2016

Breast Cancer Res Treat

View full text Add to dashboard Cite

Small cell carcinoma of the breast is a rare, aggressive form of breast cancer that is associated with extremely poor outcomes [1]. In an effort to identify possible targets for treatment, we utilized comprehensive genomic profiling in small cell carcinoma of the breast. Under an IRB approved protocol, we identified patients with small cell carcinoma of the breast and small cell carcinoma of the lung profiled by Caris Life Sciences between 2007 and 2015. Tumors were assessed with up to 25 immunohistochemical stains, in situ hybridization of cMET, EGFR, HER2, PIK3CA, and TOP2A, and next generation sequencing as well as Sanger sequencing of 47 genes. 19 patients with small cell carcinoma of the breast were identified, median age was 58 years (range 37-79) and 42 % had metastatic disease at presentation; for comparison, 58 patients with small cell carcinoma of the lung were identified (66 [36-86], 65 % metastatic). By immunohistochemistry, 31 % of small cell carcinoma of the breast patients expressed ER, 13 % expressed PR, and 16 % expressed AR; small cell carcinoma of the lung patients expressed ER 0 %, PR 2 %, and AR 6 %. Small cell carcinoma of the breast and small cell carcinoma of the lung patients had similar patterns of other immunohistochemical expression (0 v 0 % PDL1, 50 v 42 % PD1, and 77 v 95 % TOP2A, respectively). All small carcinoma of the breast and small cell carcinoma of the lung patients were negative for HER2 and cMET amplification by in situ hybridization. Next generation sequencing revealed TP53 mutations in 75 % of patients both with small cell carcinoma of the breast and small cell carcinoma of the lung and PIK3CA mutations in 33 % of small cell carcinoma of the breast patients but no small cell carcinoma of the lung patients (Fisher's exact test p = 0.005, OR 0.02 [0.00-0.52]). No other mutations were found in small cell carcinoma of the breast patients and no other mutation occurred in over 10 % of small cell carcinoma of the lung patients except RB1 in 19 % (p = 0.31). Small cell carcinoma of the breast is an aggressive tumor with few therapeutic options. Molecular profiling suggests many similarities between small cell carcinoma of the breast and small cell carcinoma of the lung with the exception an increased incidence of PIK3CA mutations in small cell carcinoma of the breast, which may have therapeutic implications.

show abstract

“…A study found that endocrine therapy or radiotherapy might improve the prognosis [ 5 ]. It was suggested that HR positive NEN patients receive endocrine therapy, especially those with SCNEC with recurrence and metastasis [ 29 ]. Endocrine therapy was also found to be effective for liver metastasis of breast cancer with neuroendocrine differentiation [ 6 ].…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological Characteristics and Prognostic Profiles of Breast Carcinoma with Neuroendocrine Features

Qiu

Dai

et al. 2023

Life

View full text Add to dashboard Cite

Background: Breast carcinoma with neuroendocrine features includes neuroendocrine neoplasm of the breast and invasive breast cancer with neuroendocrine differentiation. This study aimed to investigate the clinicopathological features and prognosis of this disease according to the fifth edition of the World Health Organization classification of breast tumors. Materials and Methods: A total of 87 patients with breast carcinoma with neuroendocrine features treated in the First Medical Center, Chinese PLA General Hospital from January 2001 to January 2022 were retrospectively enrolled in this study. Results: More than half of the patients were postmenopausal patients, especially those with neuroendocrine neoplasm (62.96%). There were more patients with human epidermal growth factor receptor 2 negative and hormone receptor positive tumors, and most of them were Luminal B type (71.26%). The multivariate analysis showed that diabetes and stage IV disease were related to the progression-free survival of breast carcinoma with neuroendocrine features patients (p = 0.004 and p < 0.001, respectively). Conclusion: Breast carcinoma with neuroendocrine features tended to be human epidermal growth factor receptor 2 negative and hormone receptor positive tumors, most of them were Luminal B type, and the related factors of progression-free survival were diabetes and stage IV disease.

show abstract

Does Hormonal Therapy Have a Therapeutic Role in Metastatic Primary Small Cell Neuroendocrine Breast Carcinoma? Case Report and Literature Review

Cited by 9 publications

References 30 publications

Primary small-cell neuroendocrine carcinoma of the male breast: a rare case report with review of the literature

Primary small-cell neuroendocrine carcinoma of the male breast: a rare case report with review of the literature

Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung

Clinicopathological Characteristics and Prognostic Profiles of Breast Carcinoma with Neuroendocrine Features

Contact Info

Product

Resources

About